Testing market acceptance and creating a positive sales environment are part of securing a licensing agreement with a major multinational company who has the scale to make the PeriCoach product a global success. Product development is a continuous process and there has been significant progress in the development of the PeriCoach.
The imminent release of version 3 of the PeriCoach, adds new, patent-pending functionality that Analytica believes will secure our position as the best technology available. The analysis of data is yielding exciting results that will assist clinicians in the diagnosis and management of urinary incontinence. Systems collecting clinical data, user testimonials and post-market surveys help establish evidence of effectiveness in treating urinary incontinence and sexual function. Focus this year will be on:
• Continuing to collect additional global clinical proof points and evaluating available data
• Cultivating Key Opinion Leaders in strategic markets • Ongoing development of the product
• Maintaining sales from existing channels to validate the product and gather further data
• Pursuing new intended uses to increase product valuation.
• Positioning the product for a license deal.
“The research and development evidenced by the V3 PeriCoach remains essential to our long-term success and the collection of data and feedback from users is critical as we continue to improve our product and create a positive sales environment with the view of securing a global sales partner for the PeriCoach,” Analytica CEO Geoff Daly said.
ALT Price at posting:
0.5¢ Sentiment: Hold Disclosure: Held
